However, clinical studies with α7 nAChR agonists have fallen short of expectations; having little effect on the cognitive problems faced by patients during the prodromal or negative symptom phase of schizophrenia (Recio-Barbero et al., 2021). The gene discussed is CHRNA7; the disease is schizophrenia.